First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15574
Abstract: EP4, a prostaglandin E2 receptor, has shown an immunosuppressive activity on cancer cells. This first‐in‐human study evaluated ONO‐4578, a highly selective EP4 antagonist, as monotherapy and in combination with nivolumab in patients with advanced or… read more here.
Keywords: combination; ono 4578; solid tumors; human study ... See more keywords
Abstract 4443: Inhibition of PGE2/EP4 pathway by ONO-4578/BMS-986310, a novel EP4 antagonist, promotes T cell activation and myeloid cell differentiation to dendritic cells
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4443
Abstract: Prostaglandin E2 (PGE2) contributes to immunosuppression in the tumor microenvironment through one or more of its receptors (EP1-EP4), especially EP4 which is expressed at high levels on myeloid cells. ONO-4578/BMS-986310 is a novel EP4-selective antagonist… read more here.
Keywords: 4578 bms; ono 4578; bms 986310; pge2 ... See more keywords